Forbes contributors publish independent expert analyses and insights. I'm a global philanthropy advisor and author of Delusional Altruism. Inaction has a price. Hesitating to put a new strategic plan ...
Turnstone Biologics Corp. has announced the discontinuation of all clinical studies related to its TIDAL-01 program due to the capital-intensive nature of manufacturing for its Selected TIL therapy ...
LEXINGTON, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced it has ...
The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did not meet the primary ...
Atkore Inc. (“Atkore” or the “Company”) (NYSE: ATKR) today announced that its Board of Directors (the “Board”) has expanded the scope of its previously announced review of strategic alternatives to ...
Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non–Small Cell Lung Cancer Artificial intelligence (AI) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results